Harvard Bioscience Q3 net loss more than doubles to $2.6 million; Q3 revenue rises 8% to $22.2 million

• Harvard Bioscience’s third-quarter 2026 net loss more than doubled year over year to $2.6 million.
• Revenue rose 8% year over year to $22.2 million.
• Project Viking remains on track for completion by the end of the first quarter of 2027.
• Full-year 2026 revenue guidance was reaffirmed at 3%-5% year-over-year growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-007308), on November 10, 2026, and is solely responsible for the information contained therein.